Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets

Pashtoon M. Kasi, Mark R Litzow, Mrinal M Patnaik, Shahrukh K. Hashmi, Naseema Gangat

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. (Clinical Trial: NCT02014558; registered at: 〈. https://clinicaltrials.gov/ct2/show/NCT02014558〉).

Original languageEnglish (US)
Pages (from-to)7-10
Number of pages4
JournalLeukemia Research Reports
Volume5
DOIs
StatePublished - 2016

Fingerprint

Clonal Evolution
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Clinical Trials
Therapeutics
Mutation
Neoplasms

Keywords

  • Acute Leukemia
  • ASP2215
  • Clonal evolution
  • FMS-like tyrosine kinase-3 (FLT3) inhibitors
  • Philadelphia chromosome (BCR-ABL)
  • Ponatinib

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. / Kasi, Pashtoon M.; Litzow, Mark R; Patnaik, Mrinal M; Hashmi, Shahrukh K.; Gangat, Naseema.

In: Leukemia Research Reports, Vol. 5, 2016, p. 7-10.

Research output: Contribution to journalArticle

@article{6e487ac6b174401e8d3baf83d13cb571,
title = "Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets",
abstract = "For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. (Clinical Trial: NCT02014558; registered at: 〈. https://clinicaltrials.gov/ct2/show/NCT02014558〉).",
keywords = "Acute Leukemia, ASP2215, Clonal evolution, FMS-like tyrosine kinase-3 (FLT3) inhibitors, Philadelphia chromosome (BCR-ABL), Ponatinib",
author = "Kasi, {Pashtoon M.} and Litzow, {Mark R} and Patnaik, {Mrinal M} and Hashmi, {Shahrukh K.} and Naseema Gangat",
year = "2016",
doi = "10.1016/j.lrr.2016.01.002",
language = "English (US)",
volume = "5",
pages = "7--10",
journal = "Leukemia Research Reports",
issn = "2213-0489",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets

AU - Kasi, Pashtoon M.

AU - Litzow, Mark R

AU - Patnaik, Mrinal M

AU - Hashmi, Shahrukh K.

AU - Gangat, Naseema

PY - 2016

Y1 - 2016

N2 - For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. (Clinical Trial: NCT02014558; registered at: 〈. https://clinicaltrials.gov/ct2/show/NCT02014558〉).

AB - For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. (Clinical Trial: NCT02014558; registered at: 〈. https://clinicaltrials.gov/ct2/show/NCT02014558〉).

KW - Acute Leukemia

KW - ASP2215

KW - Clonal evolution

KW - FMS-like tyrosine kinase-3 (FLT3) inhibitors

KW - Philadelphia chromosome (BCR-ABL)

KW - Ponatinib

UR - http://www.scopus.com/inward/record.url?scp=84954149212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954149212&partnerID=8YFLogxK

U2 - 10.1016/j.lrr.2016.01.002

DO - 10.1016/j.lrr.2016.01.002

M3 - Article

AN - SCOPUS:84954149212

VL - 5

SP - 7

EP - 10

JO - Leukemia Research Reports

JF - Leukemia Research Reports

SN - 2213-0489

ER -